Clinical trialsHigh-sensitivity C-reactive protein and cardiovascular risk in patients with coronary heart diseaseRosenson, Robert S. MD*; Koenig, Wolfgang MD†Author Information *Preventive Cardiology Center, Departments of Medicine and Preventive Medicine, Northwestern University Medical School, Chicago, Illinois, USA; †Department of Internal Medicine II-Cardiology, University of Ulm Medical Center, Ulm, Germany. Correspondence to Robert S. Rosenson, MD, Preventive Cardiology Center, Northwestern University Medical School, 201 East Huron Street, Galter Pavilion, Suite 11-120, Chicago, IL 60611, USA; e-mail: [email protected] Current Opinion in Cardiology: July 2002 - Volume 17 - Issue 4 - p 325-331 Buy Abstract High-sensitivity C-reactive protein levels have received widespread attention because of a multitude of prospective studies that have shown that high levels of high-sensitivity C-reactive protein identify increased risk of initial cardiovascular events in coronary heart disease patients and increased risk of recurrent cardiac events in patients with stable and unstable angina, patients with acute myocardial infarction, and patients undergoing elective coronary revascularization procedures. In contrast to several other inflammatory markers, high-sensitivity C-reactive protein measurements are standardized and reproducible. The clinical significance of a reliable inflammatory marker includes identification of high-risk individuals, a gauge to monitor the activity of the disease, and a potential therapeutic target to alter the inflammatory component of the disease process. This review focuses on the importance of high-sensitivity C-reactive protein in cardiovascular risk stratification in coronary heart disease patients and discusses several preventive therapies that may reduce cardiovascular risk through reduction in high-sensitivity C-reactive protein. © 2002 Lippincott Williams & Wilkins, Inc.